The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
Efficacy in moderate patients is consistent with the overall ESTEEM population
aPooled ESTEEM 1 and ESTEEM 2 studies. Post-hoc analysis of OTEZLA vs placebo at week 16 in moderate patients (baseline sPGA score of 3, BSA of 10% to 15%, PASI score of 12 to 15). A total of 224 patients met these criteria at baseline (OTEZLA, n = 160; placebo, n = 64).
bIncludes all patients in each indicated group with moderate to severe scalp psoriasis (ScPGA ≥3) at baseline; patients with a missing value at week 16 were considered non-responders.
OTEZLA improves skin plaques in moderate
patients, including patients who are biologic-naïve1*
BID, twice daily; BSA, body surface area; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index; sPGA, static Physician Global Assessment.
Efficacy in moderate patients is consistent with the overall ESTEEM population
aPooled ESTEEM 1 and ESTEEM 2 studies. Post-hoc analysis of OTEZLA vs placebo at week 16 in moderate patients (baseline sPGA score of 3, BSA of 10% to 15%, PASI score of 12 to 15). A total of 224 patients met these criteria at baseline (OTEZLA, n = 160; placebo, n = 64).
bIncludes all patients in each indicated group with moderate to severe scalp psoriasis (ScPGA ≥3) at baseline; patients with a missing value at week 16 were considered non-responders.
OTEZLA clears or minimizes scalp psoriasis in moderate
patients, including patients who are biologic-naïve1*
ScPGA, Scalp Physician Global Assessment.
Efficacy in moderate patients is consistent with the overall ESTEEM population
aPooled ESTEEM 1 and ESTEEM 2 studies. Post-hoc analysis of OTEZLA vs placebo at week 16 in moderate patients (baseline sPGA score of 3, BSA of 10% to 15%, PASI score of 12 to 15). A total of 224 patients met these criteria at baseline (OTEZLA, n = 160; placebo, n = 64).
bIncludes all patients in each indicated group with nail psoriasis at baseline (NAPSI score ≥1); patients with a missing value at Week 16 were considered nonresponders.
OTEZLA improves nail psoriasis in moderate
patients, including those who are biologic-naïve1*
NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index.
*OTEZLA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to, who have a contraindication to, or are intolerant to other systemic therapies. Moderate patients were defined as the subset of moderate to severe patients in the ESTEEM studies with an sPGA score of 3, BSA 10% to 15%, and a PASI score of 12 to 15 at baseline.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
